Cromos Pharma is closely following developments relating to the global spread of COVID-19. We are committed to protecting our employees and safeguarding the welfare of the thousands of patients in our trials while also ensuring the continuity of our clients’ research programs. Cromos Pharma is working closely with sponsors to adapt to any challenges posed by the evolving pandemic.
This COVID-19 Information Page provides updates on Cromos Pharma initiatives and programs in relation to the current crisis; regulatory news and guidance and other pertinent information regarding the impact of COVID-19 on clinical research
If you have particular queries about Cromos Pharma’s operations and COVID-19 we have set up a dedicated email to answer your questions:COVIDemail@example.com.